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To the Editor, 
I read the recent publication on cytotoxic T lym-
phocyte  antigen-4  (CTLA-4)  A49G  polymorphism 
with  a  great  interest  [1].  Aktürk  et  al.  concluded 
that,  “these  data  suggest  that  CTLA-4  A49G  poly-
morphism does not contribute to the pathogenesis 
of  lymphoproliferative  diseases  itself,  nor  does  it 
increase the risk of autoimmune complications in 
patients  with  lymphoproliferative  disease  [1].” 
Aktürk et al. tried to determine allele frequencies 
and genotype distributions for some autoimmune 
blood diseases. There are some problems with their 
conclusion.  First,  the  study  included  only  a  few 
patients  and  no  controls.  Second,  not  all  autoim-
mune  blood  diseases  were  analyzed;  therefore, 
they cannot conclude that their finding supports or 
refutes  the  contribution  of  the  studied  polymor-
phism to the pathogenesis or risk of disease. Third, 
when investigating a single polymorphism the pos-
sibility of other polymorphisms that were not inves-
tigated, must be considered.
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